Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

36.20 -0.46 (-1.27%)
Streaming Delayed Price Updated: 11:35 AM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gsk Plc ADR

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Trump's Potential 'Health Czar' Robert F. Kennedy Jr. Rattles Vaccine Stocks: 'Shoot First Reaction'
Donald Trump has said he will give Robert F. Kennedy Jr. a senior role in his incoming administration to advance his "Make America Healthy Again" agenda. 
Via Benzinga
Topics Government
Exposures Political
Moderna Posts A Surprise Profit As Sales Wallop Views. But Will RSV Be Its Undoing?
The company reported just $10 million in sales of its RSV vaccine, mResvia, widely missing expectations. 
Via Investor's Business Daily
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
The major indexes declined, but haven't fallen apart. 
Via Investor's Business Daily
GSK Stock Crumbles As Vaccine Sales Plummet And Miss Expectations
The company said revenue from RSV vaccine tumbled 72%. 
Via Investor's Business Daily
GSK's Q3 Earnings Hit By Lower Than Expected Vaccine Sales, Cautions Lower Revenue For 2024
GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines and HIV drugs show growth. 
Via Benzinga
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for millions at risk of serious disease. 
Via Benzinga
FDA Approves Pfizer's Respiratory Syncytial Virus Vaccine Abrysvo For Adults Below 60 Years
Pfizer's RSV vaccine Abrysvo receives FDA approval for adults 18-59 at high risk, with extended use for pregnant individuals to safeguard infants from birth. 
Via Benzinga
Exposures Product Safety
Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.
Korro Bio is lagging Wave Life Sciences. But an analyst says it could ultimately be the leader. 
Via Investor's Business Daily
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Moderna Hit With Another Lawsuit Related To Key COVID-19 Vaccine Technology
Northwestern University has filed a lawsuit against Moderna, alleging the company used its patented lipid nanoparticle technology without permission in the development of its COVID-19 vaccines. 
Via Benzinga
Topics Lawsuit
Exposures COVID-19 Financial Legal
GSK Seeks FDA Approval For Oral Antibiotic For Urinary Tract Infections, Probably First In New Class In Over 20 Years
GSK's gepotidacin, an oral antibiotic for uUTIs, could be the first in over 20 years. The FDA granted Priority Review with a March 2025 decision expected. Trials showed better efficacy than... 
Via Benzinga
Exposures Product Safety
Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans
Wave Life Sciences' WVE-006 demonstrates first-ever RNA editing in humans for alpha-1 antitrypsin deficiency, showing favorable safety and efficacy in early trial results. GSK holds global license... 
Via Benzinga
GSK Sues Moderna Alleging mRNA Vaccine Patent Infringement
GlaxoSmithKline has filed a lawsuit against Moderna, claiming its mRNA vaccines infringe on GSK's patents. GSK seeks royalties for Moderna's alleged unlicensed use of its groundbreaking vaccine... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction Versus Placebo At One Year
GSK's depemokimab met key endpoints in phase 3 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), showing promise in reducing nasal polyp growth and obstruction. Full results to be presented... 
Via Benzinga
2 Best Artificial Intelligence Stocks to Buy in October
These companies could have more growth ahead than investors realize. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain
GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future growth persist as challenges with its drug pipeline remain. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice
Sanofi is negotiating a potential sale of a 50% stake in its consumer health unit, Opella, to Clayton Dubilier & Rice. The deal, valued at $16.4 billion, could help Sanofi sharpen its focus on... 
Via Benzinga
GSK, Pfizer Face Declining Respiratory Syncytial Virus Vaccine Sales Due To Narrow Age Recommendations
RSV vaccine sales from GSK and Pfizer have dropped significantly following revised CDC guidelines, narrowing the eligible age group and reducing demand by two-thirds compared to last year. 
Via Benzinga
Jim Cramer Likes Reddit Very Much, Calls Accenture A 'Great Buy'
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Reddit, which went public earlier this year. 
Via Benzinga
Why GSK Stock Rocketed Nearly 6% Skyward on Wednesday
In a swarm of lawsuits, the company stood accused of selling a potentially cancer-causing medication. 
Via The Motley Fool
Topics Lawsuit
Exposures Financial Legal
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential... 
Via Benzinga
GSK Resolves Majority Of US Zantac Cases With $2.2B Settlement Deal, Stock Surges
GSK has agreed to a $2.2 billion settlement to resolve the majority of U.S. state court Zantac lawsuits, with an additional $70 million set aside for a qui tam case. The company maintains there is no... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Merck's Mumps Vaccine Controversy: Class-Action Lawsuit Alleges Anticompetitive Behavior, Court Shields From Liability
Merck faces a class-action lawsuit over alleged misrepresentation of its mumps vaccine potency, claiming anticompetitive practices to maintain market dominance. Despite ethical concerns, the court... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Pfizer Wins London Court Battle, GSK's Respiratory Syncytial Virus Vaccine Patents Invalidated
Pfizer sees stock gains following a $1 billion investment by Starboard Value and a favorable UK court ruling invalidating two GSK RSV vaccine patents. Pfizer and GSK continue their legal battles as... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report
The U.S. government collaborates with GSK, Sanofi, and CSL to enhance bird flu vaccine production. This initiative aims to increase vaccine readiness to 10 million doses by early 2025 amid rising H5... 
Via Benzinga
Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected
Guidance for the second cycle of Medicare drug price negotiations has expectations high for significant savings by 2026. 
Via Benzinga
Pfizer Divests $3.3B Stake In Sensodyne Toothpaste And Panadol Painkiller Maker Haleon
Pfizer has divested a $3.3 billion stake in Haleon, reducing its holding in the British consumer healthcare company. 
Via Benzinga
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms are bidding for the unit, with the spinoff expected by Q4 2024. Banks... 
Via Benzinga
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial results. The drug showed similar remission rates to GSK's Nucala. 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.